Augmedics
Last updated: Jul 31, 2026
Augmedics develops augmented-reality surgical navigation, led by the FDA-cleared xvision Spine System and its X2 headset. The company is shifting from direct ownership of its spine platform toward an AR innovation platform for adjacent surgical indications while VB Spine takes exclusive rights to the spine business.
Visit WebsiteCompany Overview
Augmedics is a medical-device company founded in 2014 that builds head-worn augmented-reality guidance for surgery. Its core product, the xvision Spine System, renders registered three-dimensional anatomy and navigation data in the surgeon's field of view, so instruments and implants can be aligned while the surgeon looks at the patient rather than at a remote monitor. The X2 headset, cleared by the FDA in 2025 for use with xvision, is purpose-built for the operating room: Augmedics describes a redesigned form factor, detachable surgical headlight, higher brightness, a larger field of view, higher resolution, and a more power-efficient processor. The important technical system is therefore not just a display; it combines optical see-through visualization, tracking, image registration, navigation software, and an OR-ready workflow.
The commercial problem is the cost and friction of conventional image-guided spine surgery. Navigation can improve placement confidence and support minimally invasive techniques, but many hospitals must accommodate expensive intraoperative 3D imaging, additional equipment, radiation exposure, and a workflow that repeatedly pulls the surgeon's attention toward a screen. Augmedics' open-platform positioning lets hospitals retain preferred instruments, implants, and imaging, while its CT-Fluoro registration can use a preoperative CT plus fluoroscopic images from a standard 2D C-arm rather than requiring intraoperative 3D imaging. That lowers an important infrastructure barrier, although it does not remove the need for trained staff, imaging quality, registration accuracy, sterile-process compatibility, and clinical accountability.
There is credible evidence of commercialization, but the evidence is primarily company-reported utilization rather than independently disclosed revenue or margin data. Augmedics reported more than 13,000 patients treated and more than 71,500 pedicle screws implanted across 26 US states on its current product page, following its 10,000-patient milestone in April 2025. It also reported FDA clearance for CT-Fluoro in 2024 and X2 in 2025. The company raised an $82.5 million Series D in 2023, according to its leadership announcement and funding coverage. In 2026, VB Spine announced an agreement to acquire exclusive rights to the xvision Spine System and subsequently announced a separate agreement for exclusive CT-Fluoro rights; both transactions were described as subject to closing conditions or regulatory requirements in the public announcements. This is a significant commercialization and strategic-validation signal, but it also means diligence must distinguish the value retained by Augmedics from the spine revenues, customer relationships, support obligations, and economics transferring to VB Spine.
Competition includes established navigation and robotics vendors such as Medtronic, Brainlab, Stryker, and Globus Medical, as well as newer AR or mixed-reality systems from Medivis, Surgical Theater, and other specialists. Augmedics' defensible features are its clinical history, proprietary headset and registration stack, surgeon-facing line-of-sight workflow, and compatibility with existing implants and imaging. Those advantages must withstand procurement bundling, surgeon preference, platform consolidation, and the possibility that large incumbents reproduce the interface inside broader navigation or robotic offerings.
The national-security case is real but bounded. Precision navigation, reduced attention shift, and a smaller imaging footprint could be relevant to military trauma hospitals, veteran care, disaster medicine, and surgical training. Augmedics also previously reported a Federal Supply Schedule contract giving the Veterans Health Administration access to xvision. None of those facts establishes battlefield deployment or a defense contract, and the system is currently optimized for regulated civilian spine surgery. A defense thesis would require evidence on ruggedization, cybersecurity, offline operation, sterilization and maintenance in austere environments, imaging availability, human factors under stress, and a procurement or clinical partner. The strongest strategic reading is dual-use medical guidance technology with a plausible but unproven austere-care pathway.
Dual-Use Assessment
Augmented-reality surgical navigation has substantive civilian and potential military or disaster-medicine applicability through precision guidance, reduced attention shift, and possible operation with less intraoperative imaging. The defense case remains prospective: public evidence supports veteran-health access and general medical adjacency, not battlefield deployment, ruggedized field use, or a defense contract.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Augmedics remains a credible strategic-priority signal because it has a cleared product, reported multi-thousand-patient utilization, a proprietary AR navigation stack, and a 2026 rights transaction that can place its spine technology inside a larger commercial distribution platform. The case is no longer a simple Series-stage growth story: the key diligence question is what intellectual property, adjacent-indication pipeline, personnel, economics, and support obligations remain with Augmedics after the xvision and CT-Fluoro rights transactions. A reviewer should verify transaction closing, retained assets, revenue exposure, regulatory responsibilities, customer transition, cash runway, and evidence that the company can convert spine expertise into adjacent surgical products.
Strategic Value to U.S.-Israel Alliance
Augmedics provides a strategically relevant interface and navigation layer for precision surgery. Its strongest value is the combination of head-worn visualization, registered anatomy, instrument guidance, and flexible imaging workflows in a device already used clinically. That capability could support civilian hospitals, veteran care, surgical education, and eventually constrained medical settings where attention, portability, and imaging access matter. Strategic value is moderated by the 2026 transfer of exclusive spine-platform rights to VB Spine and by the absence of public evidence for defense deployment, field ruggedization, or a broad multi-indication product portfolio.
Key Technologies
- Optical see-through augmented-reality surgical display
- Real-time 3D anatomy and instrument visualization
- Optical and electromagnetic tracking with image registration
- CT-to-fluoroscopy registration using preoperative CT and a 2D C-arm
- Purpose-built X2 headset with surgical headlight and expanded field of view
- Open-platform integration with implants, instruments, and imaging systems
- AI-assisted registration and surgical navigation software
Use Cases & Applications
- Open and minimally invasive pedicle-screw placement
- Cervical, thoracic, lumbar, sacral, and pelvic spine procedures
- Degenerative, trauma, revision, and complex-deformity surgery
- Navigation in hospitals without intraoperative 3D imaging capacity
- Radiation-conscious workflows relative to fluoroscopy-heavy techniques
- Surgeon, resident, and fellow training with anatomy-linked guidance
- Veterans Health Administration and veteran spine-care workflows
- Potential austere, disaster, or military trauma-surgery augmentation, subject to validation
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work.
This record lists 12 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- augmedics.com Public source used for profile verification.
- augmedics.com Public source used for profile verification.
- augmedics.com Public source used for profile verification.
- augmedics.com Public source used for profile verification.
- augmedics.com Public source used for profile verification.
- augmedics.com Public source used for profile verification.
- Company announcement Public source used for profile verification.
- massdevice.com Public source used for profile verification.
- accessdata.fda.gov Public source used for profile verification.
- accessdata.fda.gov Public source used for profile verification.
- augmedics.com Public source used for profile verification.
- Official website
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
Augmedics may matter as a Health & BioTech entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Augmedics's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.